2015 2014
  • In collaboration with Pfizer, Attagene publishes a paper describing the use of the MultiReporter Mouse™ model for assessing hepatotoxicity of antisense oligonucleotides in vivo.
  • In collaboration with Roswell Park Center, Attagene publishes a paper describing the use of the MultiReporter Mouse™ model for the evaluation of multiple TF responses of the mouse liver to a radioprotective drug.
  • Attagene is awarded a new contract that extends and expands collaboration with the EPA under the ToxCast™ program. Attagene will receive up to $53.4 million over the next five years for testing up to 513,000 samples in vitro and in vivo in eight FACTORIAL™ assays. (press release)

  • Attagene evaluates over 1,000 of potential endocrine disruptors under the ToxCast™ program.

  • Attagene completes Phase II ToxCast™ screening.

2011 2010
  • Attagene tests oil dispersants used in BP oil spill accident. Following the Deepwater Horizon oil spill in the Gulf of Mexico on April 20, EPA began its own testing of oil dispersants "to ensure that decisions about ongoing dispersant use… are grounded in the best available science". Attagene is urgently called upon by the EPA to apply its FACTORIAL™ assays to evaluate oil dispersants safety.

    Based on data by Attagene and others, on June 30, EPA reported that "none of the eight dispersants tested, including the product in use in the Gulf, displayed biologically significant endocrine disrupting activity." June 30 results of phase I testing. "Analysis of Eight Oil Spill Dispersants Using In Vitro Tests for Endocrine and Other Biological Activity". (publication)

  • Attagene develops and validates the MULTIREPORTER™ mouse model enabling multiplexed assessment of 48 transcription factor families in vivo. Using the MULTIREPORTER™ mouse, Attagene launches an in vivo FACTORIAL™ assay to evaluate the impact of compounds on gene regulatory pathways in the mouse liver.

  • Chemical Research in Toxicology publishes a collaborative study by Attagene and EPA ToxCast teams presenting results of Phase I ToxCast™ screening. (pdf) (press release)

  • Attagene begins Phase II ToxCast™ screening of 700 chemicals, including environmental chemicals, failed pharmaceuticals, and nanocompounds.

  • Attagene is awarded U.S. patent 7,700,284 for the FACTORIAL™ reporter system.

  • Attagene completes Phase I screening of over 300 ToxCast™ chemicals. Phase I data.

  • Attagene is named a subcontractor on a $5.3M NIH grant to a consortium led by Cleveland Biolabs for studying mitigating agents of radiation damage.

2008 2007
  • Attagene is selected by the U.S. Environmental Protection Agency (EPA) as assay provider for the EPA's ToxCast™ program. Attagene is awarded $4.04M contract by EPA for screening environmentally-relevant compounds of the ToxCast™ chemical library.

  • Attagene launches the cis-FACTORIAL™-1 reporter system enabling quantitative assessment of activities of 48 transcription factor families within cells in a single assay.

  • Attagene launches the trans-FACTORIAL™-1 reporter system eenabling quantitative assessment of ligands of 25 human nuclear receptors in a single assay.

  • Attagene is awarded $11.6 M program project grant by the NIH (subcontractor-Yale School of Medicine) to identify components of signaling pathways mediating innate immune responses.

  • Attagene is awarded $640 K SBIR Phase I NIH grant to develop novel biosensors for predictive toxicology.

  • Attagene is awarded $290 K SBIR Phase I National Institutes of Health (NIH) grant to develop novel technology to profile signal transduction pathways in cancer.

  • Attagene founded.